Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

B. infantis-based formulation PBCLN-014

An orally bioavailable formulation containing the naturally occurring lactic acid-producing gut bacteria Bifidobacterium longum subspecies infantis (B. infantis), with potential immunomodulating activity. Upon oral administration, B. infantis-based formulation PBCLN-014 may restore the unhealthy, altered gut microbiome, enhance the microbial diversity and function in the gastrointestinal (GI) tract and may re-establish a healthy microbiome in the GI tract. This may improve intestinal barrier function, suppress inflammation, enhance the patients' immunological activity and lower the risk of GI antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease (GvHD) in patients undergoing solid organ and allogeneic stem cell transplantation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Bifidobacterium longum subspecies infantis-based formulation PBCLN-014
Code name:PBCLN 014
PBCLN-014
PBCLN014
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search